GlassScriptPhysician profile
Deborah L Lindquist
NPI 1720027337
$9,718.46
in general payments reported to CMS, 2019-2025
68 companies · $2,338 in 2025
The $2,338 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2021: $44.98 · 2022: $3,180 · 2023: $1,770 · 2024: $1,821 · 2025: $2,338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,829 · Education: $99.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,828.98 |
| Education | $99.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,474.56 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $699.81 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Incyte Corporation | $515.61 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Lilly USA, LLC | $387.76 | 2022-2024 | Retevmo, Jaypirca, Verzenio |
| Pfizer INC. | $381.00 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $367.31 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Gilead Sciences, INC. | $362.50 | 2019-2025 | Trodelvy |
| Genzyme Corporation | $261.86 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $241.82 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Janssen Biotech, INC. | $229.00 | 2019-2025 | Erleada, Darzalex, Talvey |
| Daiichi Sankyo INC. | $195.49 | 2022-2025 | Enhertu, Vanflyta |
| Celgene Corporation | $185.77 | 2019-2025 | Reblozyl, Opdivo |
| Myriad Genetic Laboratories, INC. | $170.50 | 2024-2025 | Myrisk |
| Seagen INC. | $167.93 | 2019-2023 | Adcetris, Tukysa, Padcev |
| Genentech USA, INC. | $153.01 | 2023-2025 | Alecensa, Polivy, Tecentriq |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $150.53 | 2022-2025 | Onivyde, Tazverik, Somatuline Depot |
| Glaxosmithkline, LLC. | $147.72 | 2023-2025 | Zejula, Ojjaara, Jemperli |
| Sobi, INC | $134.84 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $131.71 | 2021-2025 | |
| Amgen INC. | $127.41 | 2019-2022 | |
| Abbvie INC. | $126.37 | 2024-2025 | |
| Stemline Therapeutics INC. | $124.22 | 2023-2025 | Orserdu |
| Springworks Therapeutics, INC. | $118.47 | 2024-2025 | Ogsiveo |
| Pharmacosmos Therapeutics INC. | $101.85 | 2024-2025 | Monoferric |
| Genmab U.S., INC. | $96.90 | 2023-2025 | Tivdak, Epkinly |
| Stryker Corporation | $93.19 | 2025 | Molli |
| Takeda Pharmaceuticals U.S.A., INC. | $92.14 | 2019-2025 | Iclusig, Gammagard |
| Emd Serono, INC. | $83.11 | 2019-2025 | Bavencio |
| Puma Biotechnology, INC. | $75.30 | 2019-2025 | |
| Elucent Medical | $71.25 | 2024 | |
| Tesaro, INC. | $69.85 | 2019 | |
| Rigel Pharmaceuticals, INC. | $66.43 | 2019-2024 | Tavalisse, Rezlidhia |
| Dendreon Pharmaceuticals LLC | $65.60 | 2024-2025 | Provenge |
| Pharmacyclics LLC, An Abbvie Company | $61.64 | 2019-2022 | |
| Grifols USA, LLC | $59.56 | 2024-2025 | Gamunex-C |
| Taiho Oncology, INC. | $55.15 | 2022-2025 | |
| Beone Medicines USA, INC. | $53.60 | 2025 | Tevimbra |
| Astellas Pharma US INC | $41.80 | 2023-2024 | Xospata |
| Eisai INC. | $39.38 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.00 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $38.35 | 2024 | Libtayo |
| Impedimed, INC. | $37.65 | 2025 | |
| Aveo Pharmaceuticals, INC. | $35.59 | 2022-2025 | |
| Mirati Therapeutics, INC. | $34.00 | 2023 | Krazati |
| Exelixis INC. | $33.60 | 2025 | Cabometyx |
| Caris Mpi, INC. | $32.39 | 2025 | Mi Cancer Seek |
| Geron Corporation | $32.35 | 2025 | Rytelo |
| Coherus Oncology, INC. | $30.93 | 2025 | Loqtorzi |
| Adc Therapeutics America, INC. | $27.40 | 2025 | |
| Novocure INC. | $26.71 | 2024 | Optune Lua (Novottf-200t) |
| Beigene USA, INC. | $25.89 | 2025 | Tevimbra |
| Progenics Pharmaceuticals, INC. | $25.18 | 2023 | Pylarify |
| Menarini Silicon Biosystems, INC. | $25.16 | 2024 | |
| Morphosys, US INC. | $24.85 | 2022 | |
| Iovance Biotherapeutics, INC. | $24.66 | 2025 | Amtagvi |
| Karyopharm Therapeutics INC. | $24.15 | 2022 | |
| Sun Pharmaceutical Industries INC. | $23.88 | 2025 | |
| Jazz Pharmaceuticals INC. | $23.80 | 2025 | |
| Ge Healthcare | $23.53 | 2025 | |
| Myovant Sciences INC. | $22.83 | 2022 | |
| Kyowa Kirin, INC. | $19.87 | 2024 | Poteligeo |
| Array Biopharma INC | $19.38 | 2024 | Lorbrena, Mektovi, Braftovi |
| Agios Pharmaceuticals, INC. | $19.09 | 2023 | Pyrukynd |
| Sanofi-Aventis U.S. LLC | $18.81 | 2019 | |
| Syndax Pharmaceuticals, INC. | $17.45 | 2025 | |
| Alexion Pharmaceuticals, INC. | $16.61 | 2024 | Ultomiris |
| Foundation Medicine, INC. | $13.40 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Lindquist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.